Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease, can lead to kidney enlargement and eventual loss of function. The disease affects more than 12 ...

A compound originally developed as a cancer treatment may hold promise for treating polycystic kidney disease (ADPKD), which affects more than half a million Americans and can lead to kidney ...

Bosutinib treatment was associated with a 66% decrease in the annual rate of kidney enlargement. In a phase 2 study, bosutinib, an oral drug approved for treating certain cases of chronic myeloid ...

Earlier analyses demonstrated strong local tumor control, with nearly nine in 10 patients remaining free of recurrence at ...

Polycystic kidney disease (PKD) is a debilitating hereditary condition in which fluid-filled sacs form and proliferate in the kidneys. Over time, the painful, growing cysts rob the organs of their ...

A cancer drug called bosutinib may inhibit the growth of cysts in patients with autosomal dominant polycystic kidney disease (ADPKD), according to a study appearing in an upcoming issue of the Journal ...

Expert oncologists offer closing thoughts on emerging therapeutic strategies, unmet needs, and the future of kidney cancer treatment. Chandler H. Park, MD: How I envision kidney cancer in the future ...

Liang et al matched 21,817 ESRD patients in Taiwan to patients from the general population and found the risk of developing cancer was 64% higher in the ESRD patients. 16 Lee evaluated 4,582 patients ...

Forget one-size-fits-all cancer treatments — personalization is the future, and it’s already showing promise. In a groundbreaking early-phase trial, a personalized vaccine triggered a powerful immune ...

An advantage of whole-body MRIs over CTs is that they use magnets and radio waves, which eliminate the type of radiation linked to cancer. But that doesn’t mean they’re risk-free or the right choice ...